A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers

PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated excellent inhibitory activity for both PARP1 and PARP2 enzymes. It also allosterically regulated PARP1 and PARP2 via DNA trap...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Tingting, Zhang, Zhihui, Zhou, Jie, Sheng, Li, Yao, Haiping, Ji, Ming, Xu, Bailing, Chen, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326368/
https://www.ncbi.nlm.nih.gov/pubmed/35910366
http://dx.doi.org/10.3389/fphar.2022.865085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326368/
https://www.ncbi.nlm.nih.gov/pubmed/35910366
http://dx.doi.org/10.3389/fphar.2022.865085

Ejemplares similares